申请人:Camabay Therapeutics, Inc.
公开号:EP2690095A1
公开(公告)日:2014-01-29
Aryl GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.
提供了芳基 GPR120 激动剂。这些化合物可用于治疗代谢性疾病,包括 II 型糖尿病和与血糖控制不良有关的疾病。